Journal article

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

L Tan, S Sandhu, RJ Lee, J Li, J Callahan, S Ftouni, N Dhomen, P Middlehurst, A Wallace, J Raleigh, A Hatzimihalis, MA Henderson, M Shackleton, A Haydon, V Mar, DE Gyorki, D Oudit, MA Dawson, RJ Hicks, P Lorigan Show all

Annals of Oncology | OXFORD UNIV PRESS | Published : 2019

Abstract

BACKGROUND: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tumor DNA (ctDNA) to predict and monitor relapse in resected stage III melanoma. PATIENTS AND METHODS: Somatic mutations were identified in 99/133 (74%) patients through tumor tissue sequencing. Personalized droplet digital PCR (ddPCR) assays were used to detect known mutations in 315 prospectively collected plasma samples from mutation-positive patients. External validation was performed in a prospective independent cohort (n = 29). RESULTS: ctDNA..

View full abstract

Grants

Awarded by Australian National Health and Medical Research Council


Awarded by Cancer Research UK


Awarded by Wellcome Trust


Funding Acknowledgements

This work was supported by the Australian National Health and Medical Research Council (grant number APP1107126), Cancer Research UK (grant numbers C5759/A20971) and the Wellcome Trust (grant number 100282/Z/12/Z). SJD is supported through a CSL Centenary Fellowship.